Pharmaceuticals & Biotech U.S. Community

Raj confirms store staff gets a commission for every new ELITE sign-up. That creates massive internal motivation – employees pitch ELITE customers.Read more

Renal anemia is one of the most common complications of chronic kidney disease (CKD). As kidney function declines, the production of erythropoietin (EPO) decreases, resulting in reduced stimulation of red blood cell production in the bone marrow and the development of anemia.Read more

The Hidden Bottleneck in Drug Development: Why Charles River Acquired a Cambodian Primate Supplier On January 12, 2026, Charles River Laboratories announced that it had signed an agreement to acquire the assets of K.F. (Cambodia) Ltd., a major non-human primate (NHP) breeding and supply company. [$510M] At first glance, this transaction might appear to be a routine supply chain acquisition in the contract research organization (CRO) industry.Read more

RXRX is a terrible biotech only because the INSIDERS themselves don’t believe in it! All they’re doing is milking the heck out of this doomed stock!Read more

Johnson & Johnson (JNJ): A Defensive Compounder with Steady Upside Johnson & Johnson represents a high-quality, defensive healthcare leader with resilient earnings, strong cash flow generation, and disciplined capital allocation. Following the Kenvue spin-off, JNJ is now more focused on higher-margin Pharmaceutical and MedTech segments, improving long-term growth visibility.Read more

98% of pancreatic cancer patients in Phase II study generated powerful immune responses to the KRAS antigens. Median T-cell immune response above threshold was 44-fold.Read more

"Amputation, intoxication and radiation". If students read about our current cancer treatment in 2050, they would probably date it back to 1960-70.Read more

Catalysts Successful AI-accelerated drug launches (oncology/immunology) — multi-hundred‑million to multi‑billion revenue impact. AI-enabled companion diagnostics & SaaS — recurring, high-margin revenue and better drug uptake/pricing.Read more

With the possibility of being the sole provider to combat skitsophrenia; once they complete phase three they will dominate their market. The drug brilaroxazine that they are working on has proved significant results but the FDA has made its harder for them to release it.Read more